Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C
Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Isehara, Japan.
J Am Soc Nephrol. 1998 Dec;9(12):2349-56. doi: 10.1681/ASN.V9122349.
Advanced glycation end product (AGE) formation is related to hyperglycemia in diabetes but not in uremia, because plasma AGE levels do not differ between diabetic and nondiabetic hemodialysis patients. The mechanism of this phenomenon remains elusive. Previously, it was suggested that elevation of AGE levels in uremia might result from the accumulation of unknown AGE precursors. The present study evaluates the in vitro generation of pentosidine, a well identified AGE structure. Plasma samples from healthy subjects and nondiabetic hemodialysis patients were incubated under air for several weeks. Pentosidine levels were determined at intervals by HPLC assay. Pentosidine rose to a much larger extent in uremic than in control plasma. Pentosidine yield, i.e., the change in pentosidine level between 0 and 4 wk divided by 28 d, averaged 0.172 nmol/ml per d in uremic versus 0.072 nmol/ml per d in control plasma (P < 0.01). The difference in pentosidine yield between uremic and control plasma was maintained in samples ultrafiltrated through a filter with a 5000-Da cutoff value and fortified with human serum albumin (0.099 versus 0.064 nmol/ml per d; P < 0.05). Pentosidine yield was higher in pre- than in postdialysis plasma samples (0.223 versus 0.153 nmol/ml per d; P < 0.05). These results suggest that a large fraction of the pentosidine precursors accumulated in uremic plasma have a lower than 5000 Da molecular weight. Addition of aminoguanidine and OPB-9195, which inhibit the Maillard reaction, lowered pentosidine yield in both uremic and control plasma. When ultrafiltrated plasma was exposed to 2,4-dinitrophenylhydrazine, the yield of hydrazones, formed by interaction with carbonyl groups, was markedly higher in uremic than in control plasma. These observations strongly suggest that the pentosidine precursors accumulated in uremic plasma are carbonyl compounds. These precursors are unrelated to glucose or ascorbic acid, whose concentration is either normal or lowered in uremic plasma. They are also unrelated to 3-deoxyglucosone, a glucose-derived dicarbonyl compound whose level is raised in uremic plasma: Its addition to normal plasma fails to increase pentosidine yield. This study reports an elevated level of reactive carbonyl compounds ("carbonyl stress") in uremic plasma. Most have a lower than 5000 Da molecular weight and are thus partly removed by hemodialysis. Their effect on pentosidine generation can be inhibited by aminoguanidine or OPB-9195. Carbonyl stress might contribute to AGE modification of proteins and thus to clinically relevant complications of uremia.
晚期糖基化终末产物(AGE)的形成与糖尿病中的高血糖有关,但与尿毒症无关,因为糖尿病和非糖尿病血液透析患者的血浆AGE水平并无差异。这一现象的机制仍不清楚。此前有研究表明,尿毒症中AGE水平的升高可能是由于未知AGE前体的积累所致。本研究评估了已明确的AGE结构——戊糖苷的体外生成情况。将健康受试者和非糖尿病血液透析患者的血浆样本在空气中孵育数周。每隔一段时间通过高效液相色谱法测定戊糖苷水平。与对照血浆相比,尿毒症血浆中戊糖苷升高的幅度要大得多。戊糖苷生成量,即0至4周内戊糖苷水平的变化除以28天,尿毒症血浆平均为每天0.172 nmol/ml,而对照血浆为每天0.072 nmol/ml(P<0.01)。通过截留分子量为5000 Da的滤膜超滤并添加人血清白蛋白的样本中,尿毒症血浆和对照血浆的戊糖苷生成量差异依然存在(分别为每天0.099和0.064 nmol/ml;P<0.05)。透析前血浆样本中的戊糖苷生成量高于透析后样本(分别为每天0.223和0.153 nmol/ml;P<0.05)。这些结果表明,尿毒症血浆中积累的大部分戊糖苷前体的分子量低于5000 Da。添加抑制美拉德反应的氨基胍和OPB - 9195可降低尿毒症血浆和对照血浆中的戊糖苷生成量。当超滤血浆与2,4 - 二硝基苯肼接触时,与羰基相互作用形成的腙的生成量在尿毒症血浆中明显高于对照血浆。这些观察结果强烈表明,尿毒症血浆中积累的戊糖苷前体是羰基化合物。这些前体与葡萄糖或抗坏血酸无关,它们在尿毒症血浆中的浓度要么正常要么降低。它们也与3–脱氧葡萄糖醛酮无关,后者是一种源自葡萄糖的二羰基化合物,其在尿毒症血浆中的水平升高:向正常血浆中添加该化合物并不能增加戊糖苷生成量。本研究报告了尿毒症血浆中活性羰基化合物(“羰基应激”)水平升高。大多数羰基化合物的分子量低于5000 Da,因此可通过血液透析部分清除。氨基胍或OPB - 9195可抑制它们对戊糖苷生成的影响。羰基应激可能导致蛋白质的AGE修饰,进而导致尿毒症的临床相关并发症。